[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kazia Therapeutics Ltd ADR (KZIA)

Kazia Therapeutics Ltd ADR (KZIA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,271
  • Shares Outstanding, K 1,653
  • Annual Sales, $ 1,230 K
  • Annual Income, $ -13,410 K
  • EBIT $ 0 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.61
  • Price/Sales 723.82
  • Price/Cash Flow N/A
  • Price/Book 0.64

Options Overview Details

View History
  • Implied Volatility 189.73% (-14.42%)
  • Historical Volatility 105.42%
  • IV Percentile 22%
  • IV Rank 15.85%
  • IV High 735.70% on 02/18/26
  • IV Low 86.93% on 02/13/26
  • Expected Move (DTE 19) 1.19 (9.71%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 27
  • Volume Avg (30-Day) 291
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 5,444
  • Open Int (30-Day) 1,686
  • Expected Range 11.07 to 13.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.90 +77.68%
on 03/26/26
12.40 -1.13%
on 04/24/26
+5.13 (+71.95%)
since 03/24/26
3-Month
4.86 +152.26%
on 02/12/26
12.40 -1.13%
on 04/24/26
+4.75 (+63.25%)
since 01/23/26
52-Week
3.05 +301.97%
on 05/08/25
17.40 -29.54%
on 12/08/25
+8.84 (+258.75%)
since 04/24/25

Most Recent Stories

More News
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

SYDNEY , April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced...

KZIA : 12.26 (+3.72%)
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

SYDNEY, Australia , April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment...

KZIA : 12.26 (+3.72%)
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression

KZIA : 12.26 (+3.72%)
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

SYDNEY , Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and...

KZIA : 12.26 (+3.72%)
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

SYDNEY , Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to participate in meetings...

KZIA : 12.26 (+3.72%)
Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength

KZIA : 12.26 (+3.72%)
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters

KZIA : 12.26 (+3.72%)
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

SYDNEY , Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) , an oncology-focused drug development company, today announced that it has entered into a securities purchase...

KZIA : 12.26 (+3.72%)
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

SYDNEY , Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast...

KZIA : 12.26 (+3.72%)
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

SYDNEY , Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug...

KZIA : 12.26 (+3.72%)

Business Summary

Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being...

See More

Key Turning Points

3rd Resistance Point 13.16
2nd Resistance Point 12.78
1st Resistance Point 12.52
Last Price 12.26
1st Support Level 11.88
2nd Support Level 11.50
3rd Support Level 11.24

See More

52-Week High 17.40
Last Price 12.26
Fibonacci 61.8% 11.92
Fibonacci 50% 10.22
Fibonacci 38.2% 8.53
52-Week Low 3.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.